학술논문
Phase 1 trial of a novel C'Dot drug conjugate (CDC), ELU001, in patients with solid tumors known to overexpress folate receptor alpha (FRα).
Document Type
Article
Author
Source
Journal of Clinical Oncology; 2023 Supplement 16, Vol. 41, pTPS3159-TPS3159, 1p
Subject
Language
ISSN
0732183X